Cited 0 times in Scipus Cited Count

The role of CCR1 and therapeutic effects of anti-CCL3 antibody in herpes simplex virus-induced Behcet's disease mouse model

Sayeed, HM | Lee, ES  | Byun, HO | Sohn, S
Immunology, 158(3). : 206-218, 2019
Journal Title
Behcet's disease (BD) is a chronic systemic inflammatory disease with unclear etiopathogenesis. Although gene variants of CC chemokine receptor type 1 (CCR1) have been reported, the protein expression of CCR1 in patients with BD remains unclear. The objective of this study was to analyze the frequencies of CCR1(+) cells in a herpes simplex virus-induced mouse model of BD. The frequencies of CCR1(+) cells on the surface and in the cytoplasm of peripheral blood mononuclear cells and lymph nodes were analyzed by flow cytometry. The CCR1(+) cells were significantly down-regulated in BD mice compared with the normal control and symptom-free control mice. Colchicine and pentoxifylline treatment improved the symptoms of BD and increased the frequencies of CCR1(+) cells in BD mice. Treatment with chemokine CC motif ligand 3 (CCL3), a ligand of CCR1, caused BD symptoms to deteriorate in 10 of 16 BD mice (62.5%) via down-regulation of CCR1(+) cells. Anti-CCL3 antibody treatment ameliorated BD symptoms in 10 of 20 mice (50%) and significantly decreased the disease severity score compared with CCL3-treated BD mice (P = 0.01) via up-regulation of CCR1(+) cell frequencies. In patients with BD, plasma levels of CCL3 in an active state were significantly higher than in healthy control individuals (P = 0.02). These results show that the up-regulation of CCR1(+) cells was related to the control of systemic inflammation of BD in mouse models.


Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
Journal Papers > School of Medicine / Graduate School of Medicine > Microbiology
Ajou Authors
손, 성향  |  이, 은소
Full Text Link
Files in This Item:


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.